The company has achieved the target patient recruitment (n=249) across the EU, the US & Canada in the P-II (DAZALS) study investigating dazucorilant (150mg & 300mg, daily) vs PBO for 24wks.
The 1EP of the study includes the change in ALSFRS-R to assess the motor impairment & functional decline in ALS patients from baseline and 2EPs are the OS as well as QoL. The company anticipates the clinical data by the end of 2024
Dazucorilant, a cortisol modulator, selectively binds to the glucocorticoid receptor (GR) that is currently under evaluation for ALS and has potential for various neurologic disorders
Ref: Corcept Therapeutics | Image: Corcept Therapeutics
Related News:- Verge Genomics Signs a Collaboration Agreement with Ferrer for the Development and Commercialization of VRG50635 to Treat Amyotrophic Lateral Sclerosis (ALS)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
